FDA clears Glaxo Ebola vaccine for speedy human trials

Ebola virus under an electron microscope--Courtesy of CDC

GlaxoSmithKline's ($GSK) vaccine candidate for the deadly Ebola virus is ready to roll in human trials. On Thursday, the drugmaker announced it would begin enrolling healthy patients as early as mid-September to test the investigational jab in clinical safety trials. A £2.8 million ($4.64 million) grant from several U.K. organizations--including the Wellcome Trust and the U.K. Department for International Development--will kick-start the trial. More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.